Acquisitions (Tables)

9 Months Ended

Sep. 30, 2021

2021 Acquisitions

Acquisitions

Schedule of components and fair value allocation of the consideration transferred in connection with acquisitions

The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions):

Name of Acquisition	Date Acquired		Segment		Total Consideration		Cash Consideration
Creative Instruments		July 1, 2021		BSI Life Science	$	1.0	$	1.0
SVXR, Inc.		September 9, 2021		BSI Nano		14.0		11.9
					$	15.0	$	12.9

The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions):

Name	Acquisition / Investment		Date Acquired		Segment		Consideration		Cash Consideration
Glycopath Inc.		Investment		February 18, 2021		BSI Life Science	$	2.0	$	2.0
IonPath Inc.		Investment		March 18, 2021		BSI Life Science		2.0		2.0
Olaris, Inc.		Investment		September 23, 2021		BSI Life Science		0.5		0.5
							$	4.5	$	4.5

SCI Instruments

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

The acquisition is being accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (dollars in millions):

Consideration Transferred:
Cash paid	$	28.0
Fair value of contingent consideration		1.0
Working capital adjustment		(1.0	)
Total consideration transferred	$	28.0
Allocation of Consideration Transferred:
Inventories	$	1.0
Other current and non-current assets		1.0
Intangible assets:
Technology		7.1
Customer relationships		6.4
Trade name		0.4
Backlog		1.2
Goodwill		12.6
Liabilities assumed		(1.7	)
Total consideration allocated	$	28.0